Update on Renal Sympathetic Denervation for the Treatment of Hypertension

Rao, Arundati; Krishnan, Namrata

doi:10.1007/s11886-022-01753-x

Cited by 5 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main findings are as follows. (10):1261-71 [10] and JACC Cardiovasc Interv 2019 Jun 24;12 (12):1095-105 [11]. BP, blood pressure; HR, heart rate; LVH, left ventricular hypertrophy; RAAS, renin-angiotensin-aldosterone system; RDN, renal denervation.…”

Section: Basic Rationale For Rdnmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Renal Denervation in the Treatment of Hypertension

Xiong

Chen

et al. 2023

CVIA

View full text Add to dashboard Cite

Hypertension significantly increases the risk of cardiovascular events and it is associated with high rates of disability and mortality. Hypertension is a common cause of cardiovascular and cerebrovascular accidents, which severely affect patients’ quality of life and lifespan. Current treatment strategies for hypertension are based primarily on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) has provided a new concept for the treatment of hypertension. In recent years, studies on RDN have been performed worldwide. This article reviews the latest preclinical research and clinical evidence for RDN.

show abstract

Section: Basic Rationale For Rdnmentioning

confidence: 99%

“…Figure 1 Diagram of the Efferent and Afferent Pathways Interrupted by Renal Denervation. Modified from Curr Cardiol Rep 2022 Oct;24(10):1261-71[10] and JACC Cardiovasc Interv 2019 Jun 24;12(12):1095-105[11]. BP, blood pressure; HR, heart rate; LVH, left ventricular hypertrophy; RAAS, renin-angiotensin-aldosterone system; RDN, renal denervation.…”

mentioning

confidence: 99%

Advances in Renal Denervation in the Treatment of Hypertension

Xiong

Chen

et al. 2023

CVIA

View full text Add to dashboard Cite

show abstract

“…Device‐based treatments and interventional therapies including CPAP, renal denervation (RDN), baroreflex activation therapy (BAT) and iliac arteriovenous anastomosis, etc. were reported to reduce daytime, nighttime and 24‐h BP 87–89 . Among them, CPAP and RDN had more clinical evidences.…”

Section: Treatmentmentioning

confidence: 99%

“…were reported to reduce daytime, nighttime and 24‐h BP. 87 , 88 , 89 Among them, CPAP and RDN had more clinical evidences.…”

Section: Treatmentmentioning

confidence: 99%

Management of nocturnal hypertension: An expert consensus document from Chinese Hypertension League

Liu,

Li,

Zhang

et al. 2023

J of Clinical Hypertension

View full text Add to dashboard Cite

Nocturnal hypertension is highly prevalent among Chinese and Asian populations, which is mainly attributed to high salt intake and high salt sensitivity. Nocturnal hypertension increases the risk of cardiovascular and all‐cause mortality, independent of daytime blood pressure (BP). However, it can usually be detected by 24‐h ambulatory BP monitoring, rather than routine office or home BP measurement, thus is often underdiagnosed in clinical practice. Currently, no specific guidance is available for the management of nocturnal hypertension in China or worldwide. Experts from the Chinese Hypertension League summarized the epidemiologic and pathophysiologic characteristics and clinical phenotype of nocturnal hypertension and provided consensus recommendations on optimal management of nocturnal hypertension, with the goal of maximally reducing the cardiovascular disease risks. In this consensus document, 24‐h ABPM is recommended for screening and diagnosis of nocturnal hypertension, especially in the elderly, patients with diabetes, chronic kidney diseases, obstructive sleep apnea and other conditions prone to high nocturnal BP. Lifestyle modifications including salt intake restriction, exercise, weight loss, sleep improvement, and mental stress relief are recommended. Long‐acting antihypertensive medications are preferred for nocturnal and 24‐h BP control. Some newly developed agents, renal denervation, and other device‐based therapy on nocturnal BP reduction are evaluated.

show abstract